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Abstract: The past decade has seen major advances in gene-based therapies, many of which show
promise for translation to human disease. At the forefront of research in this field is ocular disease,
as the eye lends itself to gene-based interventions due to its accessibility, relatively immune-privileged
status, and ability to be non-invasively monitored. A landmark study in 2001 demonstrating
successful gene therapy in a large-animal model for Leber congenital amaurosis set the stage
for translation of these strategies from the bench to the bedside. Multiple clinical trials have
since initiated for various retinal diseases, and further improvements in gene therapy techniques
have engendered optimism for alleviating inherited blinding disorders. This article provides
an overview of gene-based strategies for retinal disease, current clinical trials that engage these
strategies, and the latest techniques in genome engineering, which could serve as the next frontline of
therapeutic interventions.
Keywords: gene therapy; genome engineering; CRISPR; retinal degeneration; inherited
retinal disease
1. Introduction
Gene therapy holds the potential to revolutionize physicians’ ability to apply precision medicine.
Depending on the inheritance pattern of a given genetic defect, gene therapy may involve the delivery
of genetic material that either silences a pathogenic mutation or supplements patients with a wild
type copy of a mutated gene. Enthusiasm for such strategies grew quickly, until the death of a
clinical trial patient following a gene therapy-based intervention for ornithine transcarbamylase (OTC)
deficiency [1], in addition to other adverse outcomes following gene therapy [2], prompted careful
reevaluation of the ethical and safety considerations involved with such strategies. Vector choice and
delivery strategies came under close scrutiny, and additional testing in animal models was emphasized
as an essential pre-clinical safety measure.
In 1996, a team that included Drs. Bennett, Maguire and Gouras presented the first study to
use gene transfer to rescue retinal degeneration in a mouse model of retinitis pigmentosa (RP) [3].
Subretinal injection of a recombinant adenovirus carrying wild type cDNA of the phosphodiesterase β
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subunit (βPDE) effectively delayed photoreceptor degeneration in the rd mouse model, which harbors
biallelic mutations in the β subunit of rod cGMP-phosphodiesterase. Later, in 2001, injection of an
adeno-associated virus (AAV) delivering subretinal RPE65 to an RPE65−/− canine model was reported
to delay disease progression and even restore visual function [4]. These studies provided an initial
preclinical proof-of-principle for such strategies to be translated to clinical trials. Multiple groups
subsequently launched clinical trials to deliver subretinal RPE65 via an AAV vector to patients with
Leber congenital amaurosis [5–7], reinvigorating research in gene therapy.
The eye has been at the forefront of developments in gene-based technology because it possesses
several unique anatomical and physiological properties. The eye and retina are easily accessible
to physicians, and in clinical trials, the untreated eye can serve as a control if the condition
progresses symmetrically [8,9]. The optical transparency of the eye allows in vivo, longitudinal,
and non-invasive monitoring of disease progression and treatment response [10]. Moreover, the retina
can be viewed with impressively high resolution, on the scale of microns, with spectral domain optical
coherence tomography (SD-OCT), enabling visualization and delineation of the individual layers of
the retina [10,11]. Retinal imaging continues to improve, and OCT imaging can now be acquired
en face, with images oriented parallel to the plane of the retina as opposed to perpendicular, as in the
traditional SD-OCT system [11–16]. These improvements can lead to an even deeper understanding of
previously well-characterized diseases and open new doors for less-studied conditions. OCT, as well as
other imaging modalities such as fundus autofluorescence, have allowed investigators to characterize
retinal disease and identify potential outcome measures for disease progression and treatment efficacy,
supplementing traditional tests of visual function [10,17–27]. Another factor that makes the eye more
approachable to gene therapy is its relatively immune-privileged status. This is maintained by a
lack of lymphatics, immunomodulatory factors in the vitreous humor, and antigen-presenting cells,
hence leading to a significantly weaker immune response to novel antigens [28].
The advantages the eye confers for studying gene-based therapies has accelerated research
initiatives in this area, and today, there are multiple clinical trials utilizing such strategies in the
treatment of retinal disease (Table 1). This article will review some of the parameters that must be
considered for gene delivery in the eye, provide examples of applications of these techniques in current
clinical trials, and present an overview of some of the latest advances in genome surgery and their
future applications to treating inherited retinal dystrophies.
Table 1. Gene therapy trials for retinal diseases, with relevant articles cited.
Disease NCT ID & Sponsor Phase Intervention Citations
Leber Congenital
Amaurosis
NCT00999609
NCT01208389
NCT00516477
Spark Therapeutics
(Philadelphia, PA, USA)
III
I, II
I
Subretinal
AAV2-hRPE65v2 [7,29–33]
NCT00643747
University College, London
(London, UK)
I, II
Subretinal
rAAV2/2.hRPE65p.hRPE65
(tgAAG76)
[5,34–36]
NCT00749957
Applied Genetic Technologies Corp.
(Alachua, FL, USA)
I, II SubretinalrAAV2-CB-hRPE65 [37]
NCT01496040
Nantes University Hospital
(Nantes, France)
I, II SubretinalrAAV2/4.hRPE65
NCT02781480
University College, London
(London, UK)
I SubretinalAAV2/5 OPTIRPE65 [38]
NCT00481546
University of Pennsylvania
(Philadelphia, PA, USA)
I SubretinalrAAV2-CBSB-hRPE65 [39–42]
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Table 1. Cont.
Disease NCT ID & Sponsor Phase Intervention Citations
Choroideremia
NCT02077361
Ian M. MacDonald I, II
Subretinal
rAAV2.REP1
NCT02553135
Byron Lam II
Subretinal
AAV2-REP1
NCT01461213
NightstaRx
(London, UK)
I, II SubretinalAAV2.REP1 [43–45]
NCT02671539
STZ Eyetrial
(Tübingen, Germany)
II SubretinalrAAV2.REP1
NCT02341807
Spark Therapeutics
(Philadelphia, PA, USA)
I, II SubretinalAAV2-hCHM
Achromatopsia
NCT02599922
Applied Genetic
Technologies Corp.
(Alachua, FL, USA)
I, II SubretinalrAAV2tYF-PR1.7-hCNGB3 [46–48]
NCT02610582
STZ eyetrial
(Tübingen, Germany)
I, II SubretinalrAAV.hCNGA3
X-linked Retinoschisis
NCT02317887
National Eye Institute
(Bethesda, MD, USA)
I, II IntravitrealAAV8-scRS/IRBPhRS [49–52]
NCT02416622
Applied Genetic Technologies Corp.
(Alachua, FL, USA)
I, II IntravitrealrAAV2tYF-CB-hRS1 [53,54]
Leber Hereditary
Optic Neuropathy
NCT02652767
NCT02652780
GenSight Biologics
(Paris, France)
III
III
Intravitreal GS010; Sham
intravitreal injection [55]
NCT02161380
John Guy I
Intravitreal
scAAV2-P1ND4v2 [56–58]
NCT01267422
Bin Li –
Intravitreal
rAAV2-ND4 [59]
Retinitis Pigmentosa
NCT02556736
Retrosense Therapeutics
(Ann Arbor, MI, USA)
I, II IntravitrealRST-001 [60,61]
NCT01482195
Fowzan Alkuraya I
Subretinal
rAAV2-VMD2-hMERTK [62,63]
Usher Syndrome
NCT01505062
NCT02065011
Sanofi
(Paris, France)
I, II
I, II
Subretinal
EIAV-CMV-MYO7A
(UshStat)
[64]
Stargardt Disease
NCT01736592
NCT01367444
Sanofi
(Paris, France)
I, II
I, II
Subretinal
SAR422459 [65–67]
Neovascular Age-Related
Macular Degeneration
NCT01494805
Lions Eye Institute
(Perth, WA, Australia)
I, II Subretinal rAAV.sFlt-1;Control (ranibizumab alone) [68–70]
NCT01024998
Genzyme, a Sanofi company
(Cambridge, MA, USA)
I Intravitreal AAV2-sFLT01 [71–73]
NCT01301443
NCT01678872
Oxford BioMedica
(Oxford, UK)
I
I Subretinal RetinoStat [73–75]
2. Vector Choice
While there exist a variety of techniques for delivering genes into target cells, the most popular
options for use in patients include viral-mediated strategies typically involving one of two viruses:
AAVs or lentiviruses. AAV, a single-stranded DNA vector belonging to the family Parvoviridae,
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remains the vector of choice for most ocular gene therapy applications due to several advantageous
properties: AAVs elicit less immunogenic reactions than that observed from administration of
adenoviral vectors; they exhibit minimal self-replication; and they can last for up to six years after
a single administration [76,77]. Furthermore, a recombinant AAV (rAAV) capsid can be selected or
altered to suit different experimental needs and to optimize transfection [78–80]. While each of these
characteristics are advantageous for gene-based therapy, some challenges remain.
A known limitation of AAVs is their carrying capacity, which is approximately 4.5 kb,
making gene-based delivery difficult for longer genes [81]. Researchers studying delivery of genes
larger than 5 kb have circumvented this issue by utilizing dual AAV strategies. Yan et al. were
the first to employ a dual AAV strategy, effectively delivering the erythropoietin genomic locus to
mouse muscle tissue [82]. A similar study reported that this dual AAV technique could be applied to
the retina [83], and subsequent studies successfully delivered the MYO7A gene in vitro and in vivo.
Encouragingly, co-infected cells showed recombination of the two halves, leading to a full-length gene
product [84,85]. Another strategy for delivering large genes is with lentiviral vectors. Lentiviruses
are retroviruses that can carry up to 8 kb of transgene material [86]. Large genes such as MYO7A
(Usher syndrome) and ABCA4 (Stargardt disease) have been approached successfully with lentiviruses
in pre-clinical studies [64,67] and are currently being tested in clinical trials (Table 1).
3. Vector Delivery
3.1. Subretinal Injection
Most gene therapy trials for retinal degenerations involve subretinal injection of the
vector-containing therapeutic (Table 1). To accomplish this, a transient retinal detachment is made
intraoperatively to create a subretinal space to place the injection. This detachment resolves
spontaneously [9]. The viral vector subsequently occupies the subretinal space and infects target cells
of the neurosensory retina or retinal pigment epithelium (RPE). Subretinal injections are particularly
localized, which has been postulated to affect transfection and may explain the variable patterns of
functional vision improvement that were observed in the clinical trials of Leber congenital amaurosis
(LCA) [41,87]. For example, portions of the detachment that reattach first (such as the edges) may have
lower transfection [41,87,88]. Although there is no proven superior alternative to subretinal injection
for most retinal degenerations at this time, patients may benefit from more homogeneously distributed
and less invasive strategies [87].
3.2. Intravitreal Injection
The intravitreal AAV2 virus that is currently used predominantly infects the ganglion cell layer
that lies close to the vitreous cavity [89,90]. This is in comparison to subretinal injections, in which cells
in the area of the induced bleb, such as photoreceptors and RPE, are transduced [91]. For therapies
targeting the inner retina, such as in Leber hereditary optic neuropathy (LHON), the intravitreal route
of administration may prove successful in clinical trials (Table 1). The intravitreal approach is also less
invasive, thus potentially decreasing the chance for complications [92]. This may be advantageous for
retinas that are particularly at risk for retinal detachment, such as in X-linked retinoschisis (XLRS),
which is caused by mutations in retinoschisin 1 (RS1) [93]. Furthermore, RS1 protein is normally
secreted and may impart its effects on areas that are more distant to that which is transduced by
a subretinal injection [93,94]. Although the eye is considered to be immune-privileged, previous
experiments in mice suggest that the vitreous compartment may respond differently to AAV2 compared
to the subretinal space [95,96]. Li et al. found that intravitreal injection of AAV2-CBA-PEDF resulted
in a humoral immune response which prevented therapeutic effects upon readministration in a
mouse model for choroidal neovascularization [96]. The same effect was not observed via subretinal
administration. In LHON and XLRS pre-clinical studies, however, favorable safety and biodistribution
were reported for single injections of AAV-containing gene therapy administered to the vitreous,
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corroborating findings in phase I trials for LHON that report no inflammatory response of the vitreous
or anterior chamber (Table 1) [54,56–58]. Biodistribution of gene-based therapeutics delivered to the
vitreous remains complex, but pre-clinical and phase 1 clinical trial results are encouraging.
3.3. Non-Viral Strategies
To date, non-viral gene delivery strategies have not been used in human retina, but they deserve
mention due to their success and continued improvements in animal models. Electroporation is a
strategy developed by Matsuda and Cepko [97] in which DNA is directly injected in the subretinal
space without being packaged into a vector. A non-invasive, high voltage pulse is subsequently
administered, leading to changes in membrane potential and permeability, and thus cellular uptake of
the nucleic acid [98]. This method is especially useful for quickly testing promoter activity and the
effect of protein overexpression in models of retinal degeneration [97]. Previously thought to have
little therapeutic potential in humans, electroporation has advanced significantly, particularly through
suprachoroidal injection of DNA followed by ab externo electroporation, which is less invasive and
results in a large area of transfection [99].
Nanoparticles (NPs) have also been studied for the purpose of gene therapy delivery,
mainly through polymers, liposomes, and peptide-compacted DNA, which has been extensively
reviewed elsewhere [100,101]. Compared to AAV technology, NPs may be more cost-effective but have
lower transfection efficiency [102,103]. Additional advantages of NPs over AAVs include a carrying
capacity up to 20 kbp and a lower likelihood of complications, as there is less potential for insertional
mutagenesis. This technology, like electroporation, has not been translated to clinical trials but has
shown progress as an approach to ocular gene therapy [104–112].
4. Update on Gene Therapy Trials for Retinal Disease
4.1. Leber Congenital Amaurosis
LCA causes a severe early-onset retinal dystrophy with an estimated prevalence of 2–3 per
100,000 births [113]. As previously stated, gene therapy trials for RPE65-associated LCA are arguably
among the major accomplishments in modern medicine (Table 1). RPE65 is a protein required
for recycling visual pigment in the retinal pigment epithelium [114]. Mutations in RPE65 are one
cause of LCA, which typically manifests as severe visual dysfunction at birth with a pigmented
retina, wandering nystagmus, and amaurotic pupils [115]. After efficacy was shown in a naturally
occurring canine model, multiple clinical trials confirmed that an AAV vector delivering RPE65 was
safe and improved visual function during the follow-up of LCA patients [4–7,29,31–33,40,116–119].
Spark Therapeutics (Philadelphia, PA, USA) is sponsoring a phase III trial for bilateral subretinal
delivery of AAV containing RPE65. In an October 2015 press release, Spark stated the trial met its
primary endpoint of improved bilateral mobility test change score and two secondary endpoints,
which included favorable full-field light sensitivity and mobility test change scores for the first treated
eye compared to baseline. Visual acuity was a secondary outcome measure, but it was not met.
4.2. Choroideremia
Approximately 1 in 50,000 individuals are affected by choroideremia (CHM), an X-linked retinal
dystrophy [120]. Affected males typically present with night blindness and a progressively constricting
visual field, similar to retinitis pigmentosa [121]. A mutation in CHM, which expresses REP-1,
leads to chorioretinal degeneration starting in the mid-periphery. A pale fundus is observed as
the sclera illuminates through the degenerated layers of RPE and choriocapillaries. Female carriers
may exhibit changes on electroretinography despite no visual complaints [120,122]. Multiple phase
I/II studies to test the efficacy of rAAV-REP1 delivery are ongoing (Table 1). Initial findings reported
by MacLaren et al. [43] suggested improved visual function in two of six patients, even in the context
of iatrogenic retinal detachment that is required intraoperatively (NCT01461213). Increased sensitivity
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measured via microperimetry in the treated eyes correlated with vector dose per area of live retina.
A follow-up study showed sustained improvement in visual acuity of the same two patients after
3.5 years, while the control eyes continued to progress [123]. Choroideremia patients possibly have
less surgical risk when treated earlier, as one treated patient had intraoperative complications from
extensive retinal detachment. Hence, treatment may be more appropriate when there is less cell loss
and a more intact retinal structure [124].
4.3. Achromatopsia
Patients with achromatopsia, also known as rod monochromatism, typically experience decreased
visual acuity, nystagmus, photophobia, decreased color vision, and a central visual field defect.
The condition is estimated to affect 1 in 30,000 individuals [125,126]. On OCT, an optical gap can be
seen, representing foveal hypoplasia [126]. This condition is inherited recessively, and multiple genes
of the phototransduction pathway have been implicated. Most commonly, the cyclic nucleotide-gated
ion channel B3 gene (CNGB3) is mutated in patients of European descent [127]. CNGB3 encodes
a subunit of the CNG channel, which closes in the presence of a light stimulus, hyperpolarizing
the photoreceptor [128]. Applied Genetic Technologies Corporation (AGTC) (Alachua, FL, USA) is
sponsoring a phase I/II trial delivering rAAV2tYF-PR1.7-hCNGB3 to achromatopsia patients (Table 1).
Additionally, another phase I/II gene therapy clinical trial has launched in Tübingen, Germany for
patients with achromatopsia caused by defects in a similar gene, CNGA3 (Table 1).
4.4. X-Linked Retinoschisis
XLRS is a common cause of macular degeneration in young males and is estimated to affect
between 1 in 5000 and 1 in 25,000 individuals [129]. Characteristic symptoms include central vision
loss and mildly decreased visual acuity due to foveomacular schisis. A spoke-wheel appearance
encompassing the fovea is seen on fundoscopy, and OCT reveals cysts throughout the macula,
including the fovea [130]. Two phase I/II clinical trials sponsored by the National Eye Institute
(NEI) and AGTC are ongoing (Table 1). Each trial is testing therapeutic delivery of the causative gene,
RS1, utilizing a different vector and promoter. Both trials are delivering the vector via an intravitreal
injection, which is likely more ideal, as the retina in XLRS patients is fragile, and the foveomacular
schisis does not provide ideal anatomy for subretinal injection [94]. Retina specialists should carefully
assess XLRS patients for enrollment in clinical trials, as patients’ visual function may not be sufficiently
reduced to meet inclusion criteria.
4.5. Leber Hereditary Optic Neuropathy
LHON is an inherited mitochondrial disease that causes degeneration of the retinal ganglion
cells and is thus characterized by optic atrophy. The prevalence is estimated to be approximately
1 in 31,000 to 50,000 among Northern European populations, and the three most common genetic
causes are mutations in ND1, ND4, or ND6, which code for a key enzyme in cellular respiration
in mitochondria [131]. Current vectors of gene therapy cannot faithfully deliver therapeutic genes
directly into the mitochondria. Researchers overcame this challenge by demonstrating that allotopically
expressed ND4 delivered into the vitreous via an AAV vector was effective in a mouse model of
LHON [132–134]. This strategy has subsequently been translated to a clinical trial sponsored by
GenSight Biologics (Paris, France). Initial results from the open-label phase I study reported no
outstanding adverse events following administration of GS010, an AAV vector carrying normal ND4,
in patients with ND4-associated LHON. At the 90-day follow-up appointment, two patients had an
increase in visual acuity, and three patients were unchanged from baseline [58]. In the phase III study,
which is currently recruiting subjects, the effects of intravitreal GS010 injection will be compared to
a sham-control.
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4.6. Retinitis Pigmentosa
RP is a genetically heterogenous disease with nearly 80 genes associated with the condition, which
can be inherited in multiple fashions, namely dominantly, recessively, or in X-linked or mitochondrial
forms [135]. Affecting approximately 1 in 4000 individuals, RP presents at various ages with night
blindness as a first symptom. Degeneration typically starts at the mid-periphery and progresses
towards the macula, corresponding to a constricting visual field [136]. Homozygous or compound
heterozygous mutations in the mer receptor tyrosine kinase (MERTK) gene are a rare cause of autosomal
recessive RP, which is being approached with gene therapy at the King Khaled Eye Specialist Hospital
and King Faisal Specialist Hospital & Research Center (Riyadh, Saudi Arabia). Results of a phase I
trial administering rAAV2-VMD2-hMERTK to one eye in each of six patients with MERTK-associated
RP were recently reported [62]. Safety of the vector was confirmed, and three patients experienced a
post-surgical increase in visual acuity; however, this was transient in two of the patients, whose
improvements returned to baseline by the two-year follow-up appointment. Another trial for
clinically-diagnosed RP patients (mutation- and gene-independent) is assessing the efficacy of RST-001,
an intravitreally administered gene therapy that expresses a photoswitch, channelrhodopsin-2,
which allows transfected cells of the inner retina to respond to light even after photoreceptors have
degenerated (Table 1). Proof-of-principle studies in mice and marmosets supported the initiation of a
phase I/II clinical trial sponsored by Retrosense Therapeutics (Ann Arbor, MI, USA) [60,61].
4.7. Usher Syndrome
Syndromic retinitis pigmentosa associated with neurosensory hearing loss, Usher syndrome
(USH), occurs with a prevalence of approximately 3–6 per 100,000 individuals, although this may be an
underestimate [137,138]. In the absence of genetic testing, Usher syndrome can be diagnosed clinically
if irreversible hearing loss occurs in the setting of retinitis pigmentosa and a family history that
suggests an autosomal recessive inheritance pattern. Usher syndrome type 1 (USH1) is characterized
by profound hearing loss at birth, early-onset retinitis pigmentosa, and possibly decreased vestibular
function. Mutations in myosin 7a (MYO7A) can cause USH1 and are currently being studied in
gene therapy clinical trials. Normally, MYO7A is involved in protein and organelle transport across
photoreceptor cilia [139]. Because MYO7A is large and difficult to package in AAV, the drug UshStat®
was developed by Sanofi (Paris, France) to deliver the therapeutic gene in a lentivirus vector [64].
Phase II of this trial is projected to finish in 2018.
4.8. Stargardt Disease
Affecting approximately 1 in 10,000 individuals, Stargardt disease is an inherited macular
degeneration associated with dysfunction in the ATP-binding cassette, subfamily A, member 4 (ABCA4)
gene [140]. Bi-allelic pathogenic mutation of ABCA4 causes accumulation of toxic byproducts in the
RPE, which subsequently leads to cell degeneration [140]. Sanofi is studying the efficacy of SAR422459,
a lentiviral vector providing addition of the normally functioning gene (Table 1). Completion of phase
II is anticipated in 2017. In the meantime, Parker et al. have defined criteria for statistically significant
changes in functional and structural measurements in Stargardt disease progression [65].
4.9. Neovascular Age-Related Macular Degeneration
Gene therapy has also been applied to acquired retinal disease (Table 1). Age-related macular
degeneration (AMD) is the leading cause of visual impairment in the United States, and the neovascular
form, or wet AMD (wAMD), is characterized by abnormal choroidal vessel proliferation behind the
macula [68,141]. Over-secretion of vascular endothelial growth factor (VEGF) plays a key role in the
pathogenesis of neovascular AMD, and the current standard of care includes the administration of
intravitreal anti-VEGF inhibitors [142]. Gene therapy has a theoretical advantage, as long-lasting
expression would reduce or eliminate the need for repeated injections of anti-VEGF inhibitors in
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patients. Lions Eye Institute (Perth, WA, Australia) is sponsoring a trial for subretinal delivery of
rAAV.sFLT-1, and no serious ocular or systemic adverse events due to the vector were reported in
phase I/IIa trials [68,70]. Two patients experienced mild eye and anterior chamber inflammation
suspected to have been caused by rAAV.sFLT-1 administration, although the inflammation did resolve.
While the cohort receiving gene therapy required fewer additional ranibizumab injections, post-hoc
analysis revealed no significant differences in outcome measures between groups in the phase 2a
study. This may be in part due to the low number of patients enrolled (n = 32), and future trials would
be necessary to determine if rAAV.sFLT-1 is an efficacious adjunct to ranibizumab [70]. Similarly,
Genzyme, a Sanofi company (Cambridge, MA, USA) is sponsoring a phase I safety and tolerability
trial assessing intravitreal delivery of the same anti-VEGF gene therapy vector. Oxford BioMedica
(Oxford, UK) has also initiated clinical trials for subretinal RetinoStat® (GEM study), a lentivirus
containing angiostatic genes, angiostatin and endostatin, to prevent vessel growth and subsequent
vision decline (Table 1). Campochiaro et al. reported results of the GEM study, which showed
vector-containing gene therapy delivered by subretinal injection was well tolerated, and expression
levels were maintained at last measurement, which was more than 2.5 years in eight subjects and more
than 4 years in two subjects [75]. It remains to be seen if gene therapy will provide a viable treatment
option and/or adjunct for wAMD. If efficacy is demonstrated, this may represent a paradigm shift in
ophthalmic medicine, as gene therapy has traditionally been applied to monogenic diseases [70].
5. Importance of Natural Disease Characterization
The advent of clinical trials for inherited retinal disease has necessitated natural disease history
studies for various degenerations. Although gene therapy trials use the contralateral eye as a control,
it is important to study the rate of disease progression and the degree of symmetry between each eye
to validate using the untreated eye as a control. Assessing disease progression rates from large cohort
studies is additionally useful for identifying optimal functional and structural outcome measures [10].
Moreover, results from these studies aid investigators in deciding which patients are the best candidates
for gene therapy. Although it can be difficult to complete a well-powered study given the low
sample size of patients with rare degenerative diseases, several observational cohort studies are being
attempted for a variety of retinal degenerations (Table 2).
Table 2. Clinical trials for natural disease characterization of retinal degenerations.
NCT ID & Sponsor Design (Gene of Interest)
Leber Congenital
Amaurosis
NCT02575430
QLT Inc.
(Vancouver, BC, Canada)
Retrospective (LRAT & RPE65)
NCT02714816
MeiraGTx UK II Ltd.
(New York, NY, USA)
Prospective (RPE65)
NCT00422721
Nantes University Hospital
(Nantes, France)
Prospective (RPE65)
Choroideremia
NCT02994368
4D Molecular Therapeutics
(Emeryville, CA, USA)
Prospective (REP-1)
Achromatopsia
NCT01846052
Applied Genetic Technologies Corp.
(Alachua, FL, USA)
Prospective (CNGB3)
Leber Hereditary
Optic Neuropathy
NCT02796274
Santhera Pharmaceuticals
(Liestal, Switzerland)
Retrospective (G11778A, G3460A,
and T14484C mtDNA mutations)
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Table 2. Cont.
NCT ID & Sponsor Design (Gene of Interest)
X-linked
Retinoschisis
NCT00055029
National Eye Institute
(Bethesda, MD, USA)
Prospective (RS1)
Retinitis
Pigmentosa
NCT02759952
STZ Eyetrial
(Tübingen, Germany)
Prospective (PDE6A)
NCT01021982
Sheba Medical Center
(Ramat Gan, Israel)
Prospective
NCT01949623
Johns Hopkins University
(Baltimore, MD, USA)
Prospective biomarker study
NCT02926092
Shire
(Dublin, Ireland)
Prospective (RHO)
NCT00784901
National Taiwan University Hospital
(Taipei City, Taiwan)
Retrospective
Usher Syndrome
NCT00106743
National Eye Institute
(Bethesda, MD, USA)
Prospective
Stargardt Disease
NCT01977846
Foundation Fighting Blindness
Clinical Research Institute
(Columbia, MD, USA)
Retrospective & Prospective
(ABCA4)
NCT02410122
John Hopkins University
(Baltimore, MD, USA)
Prospective (PROM1)
NCT01736293
National Eye Institute
(Bethesda, MD, USA)
Prospective (ABCA4)
6. CRISPR/Cas: Ophthalmic Genome Surgery of the Future?
Clustered regularly interspaced short palindromic repeats (CRISPR) are present in bacterial and
archaeal genomes and function to provide immunity against invading viruses [143–146]. The CRISPR
locus contains integrated pieces of foreign DNA and encodes for a long transcript that is ultimately
processed intracellularly to become CRISPR-derived RNA (crRNA). Consequently, crRNAs contain
complementary sequences to the previously invading foreign DNA, and they can mediate a highly
specific, nucleic-acid based adaptive immune system by complexing with CRISPR-associated (Cas)
nucleases that induce double strand breaks (DSBs) [147]. Also within the CRISPR locus of a strain
of Streptococcus pyogenes, there exists a necessary noncoding trans-activating crRNA (tracrRNA),
which investigators combined with crRNA to form a chimeric crRNA-tracrRNA hybrid, termed guide
RNA (gRNA) [148]. Cas9 was shown to effectively be directed to specific target sequences by
custom-made gRNA in vitro, introducing a new genome-modifying toolkit which has revolutionized
the field of genetic engineering [148].
Once a double-strand break occurs in the eukaryotic genome, either non-homologous end joining
(NHEJ) or homology-directed repair (HDR) subsequently occurs to prevent cell death. NHEJ occurs
with less fidelity, as the two broken ends are directly reconnected with the possibility of insertions
and deletions, termed ‘indels’, often yielding a dysfunctional gene product. In the case of HDR,
the homologous chromosome serves as a template to ensure the broken strands contain the correct
sequence before ligation [149]. DSBs caused by the CRISPRn/Cas system (where ‘n’ denotes traditional
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CRISPR, namely to distinguish it from newer techniques, which will be discussed in subsequent
text) at a desired location induce these endogenous DNA repair mechanisms. Thus, applications of
CRISPRn/Cas have made use of the NHEJ and HDR that occurs after induction of DSBs. NHEJ occurs
more frequently compared to HDR, making the gene ‘knock-out’ strategy more readily feasible thus
far [150]. However, there is also ‘knock-in’ strategies that supplement a donor template in addition
to the gRNA and Cas protein, which consequently promotes gene repair via the HDR pathway [151].
Previous genomic engineering also required HDR to occur; however, these methods were dependent
on the low incidence of DNA damage, whereas CRISPRn creates DSBs with impressive specificity [152].
6.1. Applications to Retinal Disease
Retinal disease has been at the forefront of previous gene-based therapy research and, for the same
reasons, may prove to be amenable to CRISPRn/Cas in vivo applications. Of note, Bakondi et al. used
CRISPRn/Cas9 to ablate the mutant rhodopsin gene containing an S334ter mutation in a rat model of
dominant retinitis pigmentosa. Sub-retinal delivery of gRNA and Cas9 with subsequent electroporation
was sufficient to ablate the gain-of-function mutation and proved highly specific, as function of the
wild type allele was unaffected. Phenotypic rescue was evident with immunohistology, showing robust
photoreceptor and retinal synapse preservation [153]. This study marked the first instance where
a dominantly inherited mutant allele was amenable to ablation through CRISPRn/Cas in vivo.
In addition to this rescue experiment, CRISPRn/Cas has already been used to validate disease-causing
pathogenic gene mutations in the retina [154,155] and identify genes important for normal retinal
function and development [156–158].
Repurposing the prokaryotic CRISPRn/Cas adaptive immune system to perform gene-editing in
human cells has also been accomplished in vitro [159–162], representing a major milestone in molecular
biology [150]. For example, induced pluripotent stem cells (iPSCs) obtained from skin fibroblasts of
a patient with X-linked retinitis pigmentosa caused by an RPGR point mutation were subjected to
CRISPRn/Cas9 gene editing, producing corrected graft cells [163]. In theory, these corrected iPSCs can
be used for autologous cell transplantation, which will circumvent the need for immunosuppression.
For mature retinal cells, in vivo delivery experiments have been done with AAV2, which provided
Cas9 and sgRNA that targeted the yellow fluorescent protein (YFP) gene expressed in a transgenic
mouse [164]. This strategy effectively decreased the number of cells expressing YFP in the retina
without affecting retinal function, suggesting that applying CRISPRn/Cas to the mature retina in vivo
is feasible.
Despite rapid developments in CRISPR/Cas genome engineering, various challenges persist.
Off-target effects remain a concern for future therapeutic applications, as mutagenesis of non-desired
sites can occur at a high frequency [165]. To circumvent this issue, a catalytic domain of Cas9 was
reengineered in such a way that the nuclease could function as a nickase, which induces a single strand
break (SSB) that, in the event of an off-targeting event, will likely be less deleterious (Cas9n) [166–168].
To obtain a DSB at the desired location using Cas9n, two gRNAs are used that complement opposite
strands of the target sequence. This improves specificity by more than an order of magnitude [166–168].
Another study optimized the reduction of off-target effects in human cells, characterizing the effects of
base pair mismatch location and number in the gRNA, and the advantages of titrating the dosage of
Cas9 and gRNA [169]. Delivery poses an additional challenge for the clinical translation of CRISPR/Cas
to human disease. While the most frequently used Cas protein has a cDNA sequence that can be
packaged into AAV, its small carrying capacity does not allow much additional room for other elements,
as in the case of gene ‘knock-in’ where a donor template is required.
6.2. New Developments in CRISPR-Based Genome Engineering
While CRISPR in its traditional form has become a staple of most genetic labs, its utility has
significantly diversified as researchers began developing ways to repurpose the technology. Recently,
a strategy for reversible CRISPR-based gene editing was developed and termed CRISPR interference
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(CRISPRi). This technique employs a catalytically dead Cas (dCas) protein, which can bind but
not cleave DNA [170]. Thus, the dCas–sgRNA complex binds to the target gene and impedes
transcription by preventing RNA polymerase from binding to the promoter region or from elongating a
transcript [170]. In microbial organisms like Escherichia coli, simply replacing Cas with dCas is typically
sufficient to prevent transcription, but in mammalian cells, the efficiency of inhibition is significantly
enhanced by fusing the dCas with a repressor domain, the Krüppel-associated box (KRAB) domain
being one commonly used repressor [171]. This arrangement creates a highly programmable system
that can alter gene expression at the transcription level. The technique holds many similarities to the
conventionally used RNA interference (RNAi) system, but it has been shown to be highly sensitive to
mismatches between the sgRNA and target sequence, thus reducing off-targeting effects compared to
RNAi [172,173].
While KRAB domains can be fused with dCas, other molecules have been added to the
endonuclease to alter its activity in the opposite fashion. By fusing transcription activating domains
with dCas, gene expression can be enhanced rather than inhibited. This technique is known as
CRISPR-on or more commonly, CRISPR activation (CRISPRa) [174], and it typically involves fusion
of dCas with transactivator domain VP16, among others [175–177]. By localizing the dCas to the
promoter region of a gene, VP16 can upregulate the gene’s expression. While only minimal activation
has been obtained using this strategy, designing multiple sgRNAs for the same promoter region has
been shown to significantly augment efficiency [178]. Efforts are underway to further enhance the
efficiency of activation by recruiting additional activation domains, for example, and there remains
great enthusiasm for the future applications of this technique.
One of the newest developments in CRISPR arose from researchers seeking a means to create
single-nucleotide alterations without inducing DSBs [179,180]. They did so by fusing dCas with a
rodent cytidine deaminase called APOBEC1, which converts cytosine to uracil. Cells transfected with
the new dCas/deaminase fusion protein undergo a single cytosine to uracil conversion, which is
subsequently corrected to thymine by DNA correction mechanisms or during replication. Komor et al.
created several generations of the fusion protein to optimize its efficiency, and they dubbed the final
generation BE3. The optimized BE3 protein replaces dCas with a nickase, which, as mentioned
previously, is a catalytically active Cas protein that induces only a SSB. Although dCas results in the
fewest number of insertions and deletions (indels) in the genome due to the lack of a cleavage event,
nickase-induced SSBs also result in much fewer indels compared to the number accrued following
a DSB. The rationale for using a nickase over dCas was that by nicking the non-edited homologous
strand, the cell perceives the strand to be newly synthesized, which signals for DNA repair proteins to
correct it for errors using the edited target strand as a template. In this manner, both strands will be
edited despite only one having been cleaved. BE3 editing efficiency was further enhanced by fusing
Cas nickase with an inhibitor of the naturally occurring base excision repair process, which removes
uracil nucleotides from DNA. The overall efficiency of the system combined with the reduction in the
frequency of indels and off-targeting effects represent a considerable advancement and evolution from
the traditional application of CRISPR.
When juxtaposing all four techniques, CRISPRi and CRISPRa distinguish themselves from
traditional CRISPRn/Cas or BE3 approaches because they act at the transcriptome level, preserving
the original genome. This allows the techniques to be reversible, which confers both benefits and
detriments. The transient effects of CRISPRi/a impart a considerable advantage over CRISPRn in
obtaining FDA approval for use in clinical trials, since the patient’s own genome will remain intact and
unaltered. However, for patients with inherited retinal conditions, for example, multiple subretinal
injections to re-administer the Cas/sgRNA-containing vectors could be harmful and impractical.
A long-term, single intervention would be preferable for these patients, in which case CRISPRn or the
BE3 system might be a stronger alternative. Additionally, despite the many advantages of the BE3
technology over traditional CRISPRn/Cas, such as reduced off-targeting effects and higher overall
efficiency of editing, the current BE3 strategy is limited in its applicability. Until conversions can be
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made between adenine and guanine as well, the breadth of diseases that can be corrected using this
technique is restricted to a select subset. However, CRISPR technology has continued to advance at a
rapid pace, and it is likely that soon these techniques will be employed extensively in genetics research
and across multiple fields of medicine.
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